Which method of oral care helps to prevent oral infection for the patient who is taking fluticasone?

The combination of fluticasone and salmeterol comes as a powder and as an inhalation solution to inhale by mouth using a specially designed inhaler. It is usually used twice a day, in the morning and evening, about 12 hours apart. Use fluticasone and salmeterol at around the same times every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Use fluticasone and salmeterol exactly as directed. Do not use more or less of it or use it more often than prescribed by your doctor.

Talk to your doctor about how you should take your other oral or inhaled medications for asthma during your treatment with salmeterol and fluticasone inhalation. If you were using a short-acting beta agonist inhaler such as albuterol (Proventil, Ventolin) on a regular basis, your doctor will probably tell you to stop using it regularly but to continue to use it to treat sudden attacks of asthma symptoms. Follow these directions carefully. Do not change the way you use any of your medications or stop taking any of your medications without talking to your doctor.

Do not use fluticasone and salmeterol during an attack of asthma or COPD. Your doctor will prescribe a short-acting inhaler to use during attacks.

Fluticasone and salmeterol inhalation controls the symptoms of certain lung diseases but does not cure these conditions. It may take a week or longer before you feel the full benefit of fluticasone and salmeterol. Continue to use fluticasone and salmeterol even if you feel well. Do not stop using fluticasone and salmeterol without talking to your doctor. If you stop using fluticasone and salmeterol inhalation, your symptoms may return.

Before you use fluticasone and salmeterol inhalation (Advair Diskus, Advair HFA, or AirDuo Respiclick) for the first time, read the written package instructions that come with it. Look at the diagrams and package instructions carefully and be sure that you recognize all the parts of the inhaler. Ask your doctor, pharmacist, or respiratory therapist to show you how to use the inhaler. Practice using your inhaler while they watch, so you are sure you are doing it the right way.

If your child will be using fluticasone and salmeterol inhalation, be sure that he or she knows how to use it. Watch your child each time they use the inhaler to be sure that they are using it correctly.

Never exhale into the inhaler, take the inhaler apart, or wash the mouthpiece or any part of the inhaler. Keep the inhaler dry. Do not use the inhaler with a spacer.

Ask your pharmacist or doctor for a copy of the fluticasone and salmeterol inhalation (Advair Diskus, Advair HFA, or AirDuo Respiclick) manufacturer's information for the patient.

Fluticasone comes as an aerosol to inhale by mouth using an inhaler and as a powder to inhale by mouth using an inhaler. Fluticasone aerosol oral inhalation (Flovent HFA) is usually inhaled twice daily. Fluticasone powder for oral inhalation is usually inhaled once daily (Armonair, Arnuity Ellipta) or twice daily (Armonair Respiclick, Flovent Diskus). Try to use fluticasone at around the same times every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Use fluticasone exactly as directed. Do not use more or less of it or use it more often than prescribed by your doctor.

Talk to your doctor about how you should use your other oral and inhaled medications for asthma during your treatment with fluticasone inhalation. If you are using any other inhaled medications, ask your doctor if you should inhale these medications a certain amount of time before and after you inhale fluticasone inhalation. If you were taking an oral steroid such as dexamethasone, methylprednisolone (Medrol), or prednisone (Rayos), your doctor may want to gradually decrease your steroid dose starting at least 1 week after you begin to use fluticasone.

Fluticasone helps to prevent asthma attacks (sudden episodes of shortness of breath, wheezing, and coughing) but will not stop an asthma attack that has already started. Do not use fluticasone during an asthma attack. Your doctor will prescribe a short-acting inhaler to use during asthma attacks.

Your doctor will probably start you on an average dose of fluticasone. Your doctor may decrease your dose when your symptoms are controlled or increase it if your symptoms have not improved after at least 2 weeks.

Fluticasone controls asthma but does not cure it. Your symptoms may improve 24 hours after you begin using fluticasone, but it may take 2 weeks or longer before you feel the full benefit of the medication. Continue to use fluticasone even if you feel well. Do not stop using fluticasone without talking to your doctor.

If your child will be using the inhaler, be sure that they know how to use it. Watch your child each time they use the inhaler to be sure that they are using it correctly.

Tell your doctor if your asthma worsens during your treatment. Call your doctor if you have an asthma attack that does not stop when you use your fast-acting asthma medication, or if you need to use more of your fast-acting medication than usual.

The inhaler that comes with fluticasone aerosol is designed for use only with a canister of fluticasone. Never use it to inhale any other medication, and never use any other inhaler to inhale fluticasone.

Each product is designed to provide 30, 60, or120 inhalations, depending on the type of inhaler. After the labeled number of inhalations has been used, later inhalations may not contain the correct amount of medication. You should keep track of the number of inhalations you have used. You can divide the number of inhalations in your inhaler by the number of inhalations you use each day to find out how many days your inhaler will last. Dispose of the canister after you have used the labeled number of inhalations even if it still contains some liquid and continues to release a spray when it is pressed. Do not float the canister in water to see if it still contains medication.

Do not use your fluticasone aerosol inhaler while you are near an open flame or a heat source. The inhaler may explode if it is exposed to very high temperatures.

Before you use fluticasone the first time, read the written instructions that come with it. Look at the diagrams carefully and be sure that you recognize all the parts of the inhaler. Ask your doctor, pharmacist, or respiratory therapist to show you how to use it. Practice using the inhaler while they watch you.

1. Reddel HK, FitzGerald JM, Bateman ED, Bacharier LB, Becker A, Brusselle G, et al. GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J. 2019;53(6). [PubMed]

2. Pandya D, Puttanna A, Balagopal V. Systemic effects of inhaled corticosteroids: an overview. Open Respir Med J. 2014;8:59–65. doi: 10.2174/1874306401408010059. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

3. Ernst P, Suissa S. Systemic effects of inhaled corticosteroids. Curr Opin Pulm Med. 2012;18(1):85–89. doi: 10.1097/MCP.0b013e32834dc51a. [PubMed] [CrossRef] [Google Scholar]

4. Lipworth BJ. Risks versus benefits of inhaled β2-agonists in the management of asthma. Drug-Safety. 1992;7(1):54–70. doi: 10.2165/00002018-199207010-00007. [PubMed] [CrossRef] [Google Scholar]

5. Dusser D, Ducharme FM. Safety of tiotropium in patients with asthma. Ther Adv Respir Dis. 2019;13:1753466618824010. doi: 10.1177/1753466618824010. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

6. Thomas MS, Parolia A, Kundabala M, Vikram M. Asthma and oral health: a review. Aust Dent J. 2010;55(2):128–133. doi: 10.1111/j.1834-7819.2010.01226.x. [PubMed] [CrossRef] [Google Scholar]

7. Arafa A, Aldahlawi S, Fathi A. Assessment of the oral health status of asthmatic children. Eur J Dent. 2017;11(3):357–363. doi: 10.4103/ejd.ejd_65_17. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

8. Widmer RP. Oral health of children with respiratory diseases. Paediatr Respir Rev. 2010;11(4):226–232. doi: 10.1016/j.prrv.2010.07.006. [PubMed] [CrossRef] [Google Scholar]

9. Marsh PD, Do T, Beighton D, Devine DA. Influence of saliva on the oral microbiota. Periodontol 2000. 2016;70(1):80–92. doi: 10.1111/prd.12098. [PubMed] [CrossRef] [Google Scholar]

10. Camelo-Castillo AJ, Mira A, Pico A, Nibali L, Henderson B, Donos N, et al. Subgingival microbiota in health compared to periodontitis and the influence of smoking. Front Microbiol. 2015;6:119. doi: 10.3389/fmicb.2015.00119. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

11. Aas JA, Paster BJ, Stokes LN, Olsen I, Dewhirst FE. Defining the normal bacterial flora of the oral cavity. J Clin Microbiol. 2005;43(11):5721–5732. doi: 10.1128/JCM.43.11.5721-5732.2005. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

12. Segata N, Haake SK, Mannon P, Lemon KP, Waldron L, Gevers D, et al. Composition of the adult digestive tract bacterial microbiome based on seven mouth surfaces, tonsils, throat and stool samples. Genome Biol. 2012;13(6):R42. doi: 10.1186/gb-2012-13-6-r42. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

13. Sag C, Ozden FO, Acikgoz G, Anlar FY. The effects of combination treatment with a long-acting beta2-agonist and a corticosteroid on salivary flow rate, secretory immunoglobulin A, and oral health in children and adolescents with moderate asthma: a 1-month, single-blind clinical study. Clin Ther. 2007;29(10):2236–2242. doi: 10.1016/j.clinthera.2007.10.014. [PubMed] [CrossRef] [Google Scholar]

14. del-Río-Navarro BE, Corona-Hernández L, Fragoso-Ríos R, Berber A, Torres-Alcántara S, Cuairán-Ruidíaz V, et al. Effect of salmeterol and salmeterol plus beclomethasone on saliva flow and IgA in patients with moderate-persistent chronic asthma. Ann Allergy Asthma Immunol. 2001;87(5):420–423. doi: 10.1016/S1081-1206(10)62925-0. [PubMed] [CrossRef] [Google Scholar]

15. Global Initiative for Asthma. Difficult to treat and severe asthma in adolescent and adult patients. 2019. www.ginasthma.org.

16. Dahl R, Engel M, Dusser D, Halpin D, Kerstjens HAM, Zaremba-Pechmann L, et al. Safety and tolerability of once-daily tiotropium Respimat(®) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: a pooled safety analysis. Respir Med. 2016;118:102–111. doi: 10.1016/j.rmed.2016.07.001. [PubMed] [CrossRef] [Google Scholar]

17. Vogelberg C, Engel M, Laki I, Bernstein JA, Schmidt O, El Azzi G, et al. Tiotropium add-on therapy improves lung function in children with symptomatic moderate asthma. J Allergy Clin Immunol. 2018;6(6):2160–2162. doi: 10.1016/j.jaip.2018.04.032. [PubMed] [CrossRef] [Google Scholar]

18. Fukushima C, Matsuse H, Tomari S, Obase Y, Miyazaki Y, Shimoda T, et al. Oral candidiasis associated with inhaled corticosteroid use: comparison of fluticasone and beclomethasone. Ann Allergy Asthma Immunol. 2003;90(6):646–651. doi: 10.1016/S1081-1206(10)61870-4. [PubMed] [CrossRef] [Google Scholar]

19. Ellepola AN, Samaranayake LP. Inhalational and topical steroids, and oral candidosis: a mini review. Oral Dis. 2001;7(4):211–216. doi: 10.1034/j.1601-0825.2001.70402.x. [PubMed] [CrossRef] [Google Scholar]

20. Kurt E, Yildirim H, Kiraz N, Orman A, Metintas M, Akgun Y, et al. Oropharyngeal candidiasis with dry-powdered fluticasone propionate: 500 microg/day versus 200 microg/day. Allergol Immunopathol. 2008;36(1):17–20. doi: 10.1157/13115666. [PubMed] [CrossRef] [Google Scholar]

21. Mullaoglu S, Turktas H, Kokturk N, Tuncer C, Kalkanci A, Kustimur S. Esophageal candidiasis and Candida colonization in asthma patients on inhaled steroids. Allergy Asthma Proc. 2007;28(5):544–549. doi: 10.2500/aap2007.28.3046. [PubMed] [CrossRef] [Google Scholar]

22. Salas MMS, Nascimento GG, Huysmans MC, Demarco FF. Estimated prevalence of erosive tooth wear in permanent teeth of children and adolescents: an epidemiological systematic review and meta-regression analysis. J Dent. 2015;43(1):42–50. doi: 10.1016/j.jdent.2014.10.012. [PubMed] [CrossRef] [Google Scholar]

23. Shaw L, Dlaigan YH, Smith A. Childhood asthma and dental erosion. ASDC J Dent Child. 2000;67(2):102–106. [PubMed] [Google Scholar]

24. Dugmore CR, Rock WP. Asthma and tooth erosion Is there an association? Int J Paediatr Dent. 2003;13(6):417–424. doi: 10.1046/j.1365-263X.2003.00497.x. [PubMed] [CrossRef] [Google Scholar]

25. O’Sullivan EA, Curzon MEJ. Drug treatments for asthma may cause erosive tooth damage. BMJ. 1998;317(7161):820. doi: 10.1136/bmj.317.7161.820. [PubMed] [CrossRef] [Google Scholar]

26. Barron RP, Carmichael RP, Marcon MA, Sàndor GKB. Dental erosion in gastroesophageal reflux disease. J Can Dent Assoc. 2003;69(2):84–89. [PubMed] [Google Scholar]

27. Strużycka I, Lussi A, Bogusławska-Kapała A, Rusyan E. Prevalence of erosive lesions with respect to risk factors in a young adult population in Poland-a cross-sectional study. Clin Oral Investig. 2017;21(7):2197–2203. doi: 10.1007/s00784-016-2012-z. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

28. Harding SM. Gastroesophageal reflux, asthma, and mechanisms of interaction. Am J Med. 2001;111(8):8S–12S. doi: 10.1016/S0002-9343(01)00817-8. [PubMed] [CrossRef] [Google Scholar]

29. Pauwels A. Dental erosions and other extra-oesophageal symptoms of gastro-oesophageal reflux disease: evidence, treatment response and areas of uncertainty. United Eur Gastroenterol J. 2015;3(2):166–170. doi: 10.1177/2050640615575972. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

30. Farag ZHA, Awooda EM. Dental erosion and dentin hypersensitivity among adult asthmatics and non-asthmatics hospital-based: a preliminary study. Open Dent J. 2016;10:587–593. doi: 10.2174/1874210601610010587. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

31. Löe H, Brown LJ. Early onset periodontitis in the United States of America. J Periodontol. 1991;62(10):608–616. doi: 10.1902/jop.1991.62.10.608. [PubMed] [CrossRef] [Google Scholar]

32. Mehta A, Sequeira PS, Sahoo RC, Kaur G. Is bronchial asthma a risk factor for gingival diseases? A control study. N Y State Dent J. 2009;75(1):44–46. [PubMed] [Google Scholar]

33. McDerra EJ, Pollard MA, Curzon ME. The dental status of asthmatic British school children. Pediatr Dent. 1998;20(4):281–287. [PubMed] [Google Scholar]

34. Stensson M, Wendt L-K, Koch G, Oldaeus G, Ramberg P, Birkhed D. Oral health in young adults with long-term, controlled asthma. Acta Odontol Scand. 2011;69(3):158–164. doi: 10.3109/00016357.2010.547516. [PubMed] [CrossRef] [Google Scholar]

35. Moraschini V, Calasans-Maia JA, Calasans-Maia MD. Association between asthma and periodontal disease: a systematic review and meta-analysis. J Periodontol. 2018;89(4):440–455. [PubMed] [Google Scholar]

36. Ferreira MKM, Ferreira RO, Castro MML, Magno MB, Almeida AP, Fagundes APCPSC, et al. Is there an association between asthma and periodontal disease among adults? Systematic review and meta-analysis. Life Sci. 2019;223:74–87. doi: 10.1016/j.lfs.2019.03.005. [PubMed] [CrossRef] [Google Scholar]

37. Han E-R, Choi IS, Kim H-K, Kang Y-W, Park J-G, Lim J-R, et al. Inhaled corticosteroid-related tooth problems in asthmatics. J Asthma. 2009;46(2):160–164. doi: 10.1080/02770900802553102. [PubMed] [CrossRef] [Google Scholar]

38. Heffler E, Madeira LNG, Ferrando M, Puggioni F, Racca F, Malvezzi L, et al. Inhaled corticosteroids safety and adverse effects in patients with asthma. J Allergy Clin Immunol. 2018;6(3):776–781. doi: 10.1016/j.jaip.2018.01.025. [PubMed] [CrossRef] [Google Scholar]

39. Shen T-C, Chang P-Y, Lin C-L, Wei C-C, Tu C-Y, Hsia T-C, et al. Risk of periodontal disease in patients with asthma: a nationwide population-based retrospective cohort study. J Periodontol. 2017;88(8):723–730. doi: 10.1902/jop.2017.160414. [PubMed] [CrossRef] [Google Scholar]

40. Mehtonen IT, Rantala AK, Hugg TT, Jaakkola MS, Jaakkola JJK. Dental caries is associated with lower respiratory tract infections: a population-based cohort study. Respir Med. 2019;158:1–5. doi: 10.1016/j.rmed.2019.09.002. [PubMed] [CrossRef] [Google Scholar]

41. Bjerkeborn K, Dahllof G, Hedlin G, Lindell M, Modéer T. Effect of disease severity and pharmacotherapy of asthma on oral health in asthmatic children. Eur J Oral Sci. 1987;95(2):159–164. doi: 10.1111/j.1600-0722.1987.tb01824.x. [PubMed] [CrossRef] [Google Scholar]

42. Eloot AK, Vanobbergen JN, De Baets F, Martens LC. Oral health and habits in children with asthma related to severity and duration of condition. Eur J Paediatr Dent. 2004;5(4):210–215. [PubMed] [Google Scholar]

43. Alavaikko S, Jaakkola MS, Tjäderhane L, Jaakkola JJK. Asthma and caries: a systematic review and meta-analysis. Am J Epidemiol. 2011;174(6):631–641. doi: 10.1093/aje/kwr129. [PubMed] [CrossRef] [Google Scholar]

44. Choi H, Bae K-H, Lee J-W. Association between age at asthma diagnosis and tooth loss. Acta Odontol Scand. 2018;76(7):466–472. doi: 10.1080/00016357.2018.1436723. [PubMed] [CrossRef] [Google Scholar]

45. Milano M, Lee JY, Donovan K, Chen J-W. A cross-sectional study of medication-related factors and caries experience in asthmatic children. Pediatr Dent. 2006;28(5):415–419. [PubMed] [Google Scholar]

46. Reddy DK, Hegde AM, Munshi AK. Dental caries status of children with bronchial asthma. J Clin Pediatr Dent. 2003;27(3):293–295. [PubMed] [Google Scholar]

47. Wogelius P, Poulsen S, Sørensen HT. Use of asthma-drugs and risk of dental caries among 5 to 7 year old Danish children: a cohort study. Commun Dent Health. 2004;21(3):207–211. [PubMed] [Google Scholar]

48. Bozejac BV, Stojšin I, Ðuric M, Zvezdin B, Brkanić T, Budišin E, et al. Impact of inhalation therapy on the incidence of carious lesions in patients with asthma and COPD. J Appl Oral Sci. 2017;25(5):506–514. doi: 10.1590/1678-7757-2016-0147. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

49. Bousquet J, Schünemann HJ, Togias A, Bachert C, Erhola M, Hellings PW, et al. Next-generation allergic rhinitis and its impact on asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70–80. doi: 10.1016/j.jaci.2019.06.049. [PubMed] [CrossRef] [Google Scholar]

50. Chuang CY, Sun HL, Ku MS. Allergic rhinitis, rather than asthma, is a risk factor for dental caries. Clin Otolaryngol. 2018;43(1):131–136. doi: 10.1111/coa.12912. [PubMed] [CrossRef] [Google Scholar]

Page 2

PMC full text:

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Possible causes of dental erosion

Reduction of salivary flow rate due to beta 2 agonists
Increase in teeth’s exposure to acid
 Extrinsic sources: acid soft drinks, acidity of medications (inhalers, in particular dry powder)
 Intrinsic sources: gastroesophageal reflux